178261-41-1

Usage

Uses

Used in Pharmaceutical Industry:
1-(methylsulfonyl)spiro[indoline-3,4'-piperidine] is used as a pharmacological agent for its activity as a dopamine D3 receptor antagonist, which is crucial in the treatment of neurological and psychiatric disorders. Its ability to modulate dopamine signaling pathways makes it a promising candidate for the development of new drug therapies targeting these conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1-(methylsulfonyl)spiro[indoline-3,4'-piperidine] serves as an interesting target for research due to its unique spirocyclic structure and the presence of a sulfone functional group. 1-(methylsulfonyl)spiro[indoline-3,4'-piperidine]'s potential as a lead molecule for the design and synthesis of novel therapeutic agents highlights its importance in the discovery of new drugs for various medical applications.
Used in Synthetic Chemistry Research:
1-(methylsulfonyl)spiro[indoline-3,4'-piperidine] is also utilized in synthetic chemistry research, where its complex structure and functional group provide opportunities for the development of innovative synthetic routes and methodologies. The exploration of its synthesis can contribute to the advancement of chemical techniques and the creation of new compounds with potential applications in various fields.

Upstream product

• 138163-08-3 N-(benzyloxycarbonyl)piperidine-4-carboxaldehyde 
• 24686-78-0 1-Benzoyl-4-piperidone 
• 34259-90-0 1-benzoyl-4-nitromethyl-piperidin-4-ol 
• 6751-75-3 2-bromoresorcinol 
• 122860-33-7 benzyl 4-(hydroxymethyl)piperidine-N-carboxylate 
• 100-63-0 phenylhydrazine 
• 6457-49-4 4-piperidinemethanol 
• 167484-18-6 benzyl spiro[indoline-3,4’-piperidine]-1‘-carboxylate 
• 184289-85-8 benzyl spiro[indole-3,4'-piperidine]-1'-carboxylate 
• 10314-99-5 benzyl 4-(chlorocarbonyl)piperidine-1-carboxylate 
• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 498-94-2 isonipecotic acid 
• 184289-84-7 benzyl 1-(methylsulfonyl)spiro[indoline-3,4’-piperidine]-1‘-carboxylate 

Downstream Products

• 180465-66-1 C₂₈H₃₇N₃O₆S 
• 159634-47-6 Ibutamoren 
• 180465-67-2 C₂₃H₂₉N₃O₄S 
• 159634-87-4 N-[(R)-[(1,2-Dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(phenylmethyloxy)ethyl]-2-[(1,1-dimethyl-ethoxy)carbonyl]amino-2-methyl-propanamide 
• 191487-52-2 MK-677 
• 268537-75-3 1-Methylsufonyl-N-(4-ethoxycarbonylphenyl)spiro[indoline-3,4'-piperidine]-1'-carboxamide 
• 1148009-61-3 C₂₆H₂₇N₃O₃S 
• 1185761-74-3 1-(methylsulfonyl)-N-[4-(pyridin-3-yl)phenyl]-1,2-dihydro-1'H-spiro[indole-3,4'-piperidine]-1'-carboxamide 

Relevant academic research and scientific papers

Domino Aryne Annulation via a Nucleophilic-Ene Process

1,2-Benzdiyne equivalents possess the unique property that they can react with two arynophiles through iteratively generated 1,2- and 2,3-aryne intermediates. Upon rational modification on the second leaving group of these aryne precursors, a domino aryne annulation approach was developed through a nucleophilic-ene reaction sequence. Various benzo-fused N-heterocyclic frameworks were achievable under transition metal-free conditions with a broad substrate scope.

SUBSTITUTED HETEROCYCLIC DERIVATIVES AS GPR AGONISTS AND USES THEREOF

The present invention generally relates to substituted heterocyclic derivatives (the compounds of Formula (I)), processes for their preparation, pharmaceutical compositions containing said compounds, their use as G-protein coupled receptor (GPR) agonists, particularly as GPR40 agonists and methods of using these compounds in the treatment of GPR40 mediated diseases or conditions such as Type 2 diabetes, obesity, dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

A facile synthesis of the spiroindoline-based growth hormone secretagogue, MK-677

A facile and improved route for the synthesis of the orally active spiroindoline-based growth hormone secretagogue, MK-677 was described. The key step adopted the Fischer indole/reduction strategy. The preparation of the key intermediates N-protected piperidine carboxaldehyde 5 and the N-Boc-O-benzyl-d-serine (2) are also optimized.

INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS

The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.

THERAPEUTIC COMPOUNDS AND USES THEREOF

Compounds of formula (I) are described herein The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.

SULFONAMIDES AND USES THEREOF

Compounds of formulas (I), (II), (III), and (IV) and methods of treating disorders by administering a compound of formula (I), (II), (III), or (IV) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.

CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS

The present invention relates to cyclopropyl derivatives of formula (I) and salt thereof. These compounds are NK3 receptor antagonists and may therefore be useful for treatment of diseases where the NK3 receptor is implicated, e.g. psychotic disorders.

Synthesis of the orally active spiroindoline-based Growth Hormone Secretagogue, MK-677

The preparation of the Merck Growth Hormone Secretagogue; MK-677 is described. A Fischer indole/reduction based strategy provides the novel spiroindoline nucleus of this potent compound. This optimized sequence necessitates the isolation of only one intermediate 10 and provides MK-677 in 48% overall yield from isonipecotic acid 3.